Sign In
7 Mar 2014 15:03
For immediate release | 7 March 2014 |
ABCAM PLC
("Abcam" or "the Company")
Director's dealings
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of innovative protein research tools, was notified on 6 March 2014 that a trust, of which Dr Jonathan Milner, a Director of the Company, is a trustee, sold 47,000 Ordinary Shares of 0.2p each in the Company at a price of 424 pence per share.
On the same day, Dr Milner transferred 685,000 Ordinary Shares of 0.2p each in the Company to his wife, Mrs Roza Gounari for nil consideration.
On 7 March 2014 Dr Milner exercised share options over 603,746 Ordinary Shares of 0.2p each of which 230,020 had an exercise price of 82.6p, 16,590 had an exercise price of 180.8p and 357,136 had an exercise price of 0.2p.
Following these transactions, Dr Milner's total interest in the Company has increased by 603,746 Ordinary Shares and is now 27,155,855 Ordinary Shares of 0.2p each, representing approximately 13.6% of the Company's issued share capital. This total interest is constituted as follows:
Beneficial Interest |
27,100,355 |
Non-Beneficial Interest: | 55,500 |
For further information please contact:
Abcam | + 44 (0) 1223 696 000 |
Jeff Iliffe, Chief Financial Officer
| |
Numis Securities - Nominated Adviser & Joint Broker | + 44 (0) 20 7260 1000 |
Michael Meade - Nominated Adviser | |
James Black - Corporate Broking
| |
Peel Hunt LLP - Joint Broker | + 44 (0) 20 7418 8900 |
Clare Terlouw / Jock Maxwell MacDonald
| |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
Notes for editors:
About Abcam plc
Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level to improve the understanding of health and disease.
Abcam is committed to providing scientists with access to the correct reagents and tools for their research. The Company's catalogue currently comprises more than 129,000 products and is continually evolving to meet customer needs. The range offered includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam products are supported with detailed, up-to-date and unbiased data on our website.
Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices and ships to over 100 countries. The Company was founded in 1998, and now employs over 700 people. Abcam is quoted on the AIM market of the London Stock Exchange (AIM: ABC).
To find out more, please visit www.abcam.com
Follow the stocks
